As of April 11, 2023, word on the street is that a significant pharmaceutical company has its sights set on acquiring Aldeyra Therapeutics, a biotech firm specializing in immune-mediated disease treatments. While Aldeyra recently wrapped up its Phase 2 clinical trial of an orally administered RASP modulator, there has been no official word on the acquisition rumor. The company only proposed a public offering of common stock in February of this year.
https://beststocks.com/rumors-of-acquisition-surrounding-aldeyra-the/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.